Advanced Oncotherapy #AVO – Final Results statement plus CEO and Chairmans report

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2017, another year of significant technological development and installation of the Company’s first LIGHT system. Key highlights: ·     Successful integration of three of the four key LIGHT system structures significantly reducing technical […]

Advanced Oncotherapy #AVO – Notice of General Meeting

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a circular convening the Company’s General Meeting to be held at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD at 10:00am on Tuesday, 23 January 2018, in relation to the transactions announced on 7 December 2017 has […]

Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 […]

Advanced Oncotherapy (AVO) – Interim results announcement

Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and post-period events.  Highlights: ·     Technological milestones reached with successful integration and testing of proton source, RFQ and SCDTL significantly de-risking development process ·     Progress at the Harley Street […]

AVO – More LIGHT at the end of the tunnel – Wall Street Wires

by Spekulator at Wall Street Wires Quick reminder. I am an active investor into smaller companies where I see (a) genuine value (b) good management (c) an unusual or groundbreaking product. Mostly a,b and c have to be present and correct, but I will make exceptions. I am invested into companies listed on Nasdaq, London […]

Advanced Oncotherapy (AVO) – Final results

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2016, another year of significant development of the Company’s LIGHT system. Highlights: ·     First successful acceleration of the proton beam through the proton source and Radio Frequency Quadrupole (RFQ) ·     Successful […]

AVO – Give me some LIGHT – Wall Street Wires

by Spekulator at Wall Street Wires An introduction. I am an active investor into smaller companies where I see (a) genuine value (b) good management (c) an unusual or groundbreaking product. Mostly a,b and c have to be present and correct, but I will make exceptions. I am invested into companies listed on Nasdaq, London […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday the Directors below purchased ordinary shares of 25 pence in the Company. Director No of Ordinary Shares purchased   Price paid Resultant shareholding   %  of the issued share capital Dr Michael Sinclair, Executive Chairman 100,000 28.35p 4,728,229 6.51% Dr […]

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Friday 24 March it signed an additional 12-month convertible and redeemable loan, at a conversion price of 100p, which will provide net funding of £3m, with an option to draw-down a further £2m within the next […]